Br J Haematol

1. LI Y, Jin L, Liu W, Liu Y, et al
   Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.
   Br J Haematol. 2025 Sep 16. doi: 10.1111/bjh.70097.
   

   >> Share

   
   
2. KHAVANDI MM, Strati P, Habibollahi P
   Minimally invasive percutaneous lymphangiography and embolisation for spontaneous chyle leaks in patients with lymphoma.
   Br J Haematol. 2025 Jul 15. doi: 10.1111/bjh.70007.
   

   >> Share

   
   
3. NORDKIN M, Fadaos N, Leiba R, Sharon-Horesh N, et al
   Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm.
   Br J Haematol. 2025;207:1104-1107.
   

   >> Share

   
   
4. BAHABRI AS, Lau C, Kim VHD, Alexander S, et al
   Incidence and impact of prior history of serious infection in paediatric lymphoma: A population-based study.
   Br J Haematol. 2025 Sep 15. doi: 10.1111/bjh.70157.
   

   >> Share

   
   
5. BARONE A, De Philippis C, Stella F, Dodero A, et al
   Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes.
   Br J Haematol. 2025;207:956-964.
   

   >> Share

   
   
6. JO T, Arai Y, Shimizu T, Kitawaki T, et al
   Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post-CAR-T-cell therapy.
   Br J Haematol. 2025;207:1002-1010.
   

   >> Share

   
   
7. JOHNSTONE P, Higgins M, Prince HM, Lade S, et al
   Large-cell transformation of mycosis fungoides: Patterns of care and patient outcomes.
   Br J Haematol. 2025;207:824-833.
   

   >> Share

   
   

   
   Cancer

8. NIERENGARTEN MB
   Safety and promising efficacy with enhanced CAR T-cell therapy for lymphoma.
   Cancer. 2025;131:e70035.
   

   >> Share

   
   

   
   Eur J Haematol

9. CASERTA S, Martino EA, Vigna E, Bruzzese A, et al
   Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
   Eur J Haematol. 2025 Sep 13. doi: 10.1111/ejh.70036.
   

   >> Share

   
   

   
   Haematologica

10. SANTORO A, Improta CM, Sarina B, Mannina D, et al
    Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma.
    Haematologica. 2025 Sep 18. doi: 10.3324/haematol.2025.287672.
    

    >> Share

    
    

    
    J Am Acad Dermatol

11. BRUMBAUGH B, Westmeijer M, Thompson B, Holt A, et al
    Risk of Cutaneous T-cell Lymphoma in Patients with Autoimmune Diseases.
    J Am Acad Dermatol. 2025 Sep 11:S0190-9622(25)02793.
    

    >> Share

    
    

    
    N Engl J Med

12. OKADA S, Nishikubo M
    Subcutaneous Panniculitis-like T-Cell Lymphoma.
    N Engl J Med. 2025;393:1117.
    

    >> Share

    
    

    
    PLoS One

13. CHEN L, Lu Z, Zhang X, Lai J, et al
    Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients.
    PLoS One. 2025;20:e0332421.
    

    >> Share

    
    
14. SAAD M, Aisha E, Sohail MU, Sajid M, et al
    Trends and disparities in Non-Hodgkin Lymphoma related mortality in the United States, 1999-2020.
    PLoS One. 2025;20:e0327809.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share